Broutier et al. identified an ERK inhibitor as a potential therapeutic treatment with human primary cancer organoids in 2017.18 In the same year, Crespo et al. developed colonic organoids from patients with familial adenomatous polyposis coli (FAP) that incorporated mutations in a negative regulator of the WNT pathway called the adenomatous polyposis coli (APC) gene.202 They also screened two compounds that were effective in rescuing the overproliferation of patients’ organoids, which could also affect wild-type organoids. The gene discussed is APC; the disease is cancer.